NO319867B1 - Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff. - Google Patents

Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff. Download PDF

Info

Publication number
NO319867B1
NO319867B1 NO19963097A NO963097A NO319867B1 NO 319867 B1 NO319867 B1 NO 319867B1 NO 19963097 A NO19963097 A NO 19963097A NO 963097 A NO963097 A NO 963097A NO 319867 B1 NO319867 B1 NO 319867B1
Authority
NO
Norway
Prior art keywords
humanized
mouse
human
immunoglobulin
variable region
Prior art date
Application number
NO19963097A
Other languages
English (en)
Norwegian (no)
Other versions
NO963097D0 (no
NO963097L (no
Inventor
Jose William Saldanha
Mary M Bendig
Olivier J Leger
Tarran S Jones
Ted Yednock
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of NO963097D0 publication Critical patent/NO963097D0/no
Publication of NO963097L publication Critical patent/NO963097L/no
Publication of NO319867B1 publication Critical patent/NO319867B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO19963097A 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff. NO319867B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Publications (3)

Publication Number Publication Date
NO963097D0 NO963097D0 (no) 1996-07-24
NO963097L NO963097L (no) 1996-09-24
NO319867B1 true NO319867B1 (no) 2005-09-26

Family

ID=22684288

Family Applications (3)

Application Number Title Priority Date Filing Date
NO19963097A NO319867B1 (no) 1994-01-25 1996-07-24 Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff.
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO2006008C NO2006008I2 (no) 1994-01-25 2006-08-07 Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
NO2017040C NO2017040I2 (no) 1994-01-25 2017-08-01 Natalizumab, anti alfa-4 integrin humanisert monoklonalt antistoff - forlenget SPC

Country Status (21)

Country Link
EP (2) EP0804237B8 (de)
JP (5) JP4115517B2 (de)
KR (1) KR100367948B1 (de)
CN (1) CN1211123C (de)
AT (1) ATE333895T1 (de)
AU (1) AU703152B2 (de)
CA (1) CA2182013C (de)
DE (2) DE69535133T2 (de)
DK (2) DK1759709T3 (de)
ES (2) ES2424292T3 (de)
FI (1) FI117509B (de)
FR (1) FR06C0024I2 (de)
HU (1) HU220799B1 (de)
LU (1) LU91271I2 (de)
MX (1) MX9602971A (de)
NL (1) NL300238I2 (de)
NO (3) NO319867B1 (de)
NZ (1) NZ279730A (de)
PL (1) PL181827B1 (de)
PT (1) PT804237E (de)
WO (1) WO1995019790A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP2065050A1 (de) * 1998-09-14 2009-06-03 Board of Regents, The University of Texas System Verfahren zur Behandlung von multiplem Myelom und von Myelom induzierter Knochenresorption unter Anwendung von Integrin-Antagonisten
CN1332714C (zh) 1999-04-22 2007-08-22 比奥根艾迪克Ma公司 整联蛋白α4亚单位的拮抗剂在制备治疗纤维变性的药物组合物中的用途
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
IL146508A0 (en) 1999-06-01 2002-07-25 Biogen Inc A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003517023A (ja) * 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GEP20074252B (en) 2001-04-13 2007-12-10 Biogen Idec Inc Antibodies to vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
US7371383B2 (en) * 2002-04-12 2008-05-13 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
KR101194176B1 (ko) 2003-12-22 2012-10-24 아지노모토 가부시키가이샤 신규한 페닐알라닌 유도체
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
MX2008014793A (es) 2006-05-25 2008-12-02 Biogen Idec Inc Metodos para tratar la apoplejia.
EP2124996A4 (de) 2007-02-20 2010-03-24 Merrimack Pharmaceuticals Inc Verfahren zur behandlung von multipler sklerose mittels verabreichung eines alpha-fetoproteins in kombination mit einem integrinantagonisten
EP2170390B1 (de) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab-antikörper-formulierungen
EP2221325B1 (de) 2007-12-13 2014-04-16 Tokuyama Corporation Photochrome härtbare zusammensetzung
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
SMT202000306T1 (it) 2010-04-16 2020-07-08 Biogen Ma Inc Anticorpi anti-vla-4
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
CA2864539C (en) 2012-02-16 2022-06-07 Santarus, Inc. Antibody formulations
WO2018002036A1 (en) 2016-06-28 2018-01-04 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
EP3541413A2 (de) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Wässrige pharmazeutische formulierungen
DK3583126T3 (da) * 2017-02-17 2025-11-17 Sanofi Sa Multispecifikke bindingsmolekyler med specificitet for dystroglycan og laminin-2
EP3635093A1 (de) 2017-06-08 2020-04-15 Polpharma Biologics S.A. Verbesserte zellkulturverfahren
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
JPH07506566A (ja) * 1992-02-12 1995-07-20 バイオゲン　インコーポレイテッド 炎症性胃腸病の処置
DK0678122T3 (da) * 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
EP0804237A4 (de) 2003-04-16
DE122006000043I1 (de) 2007-02-15
PL315634A1 (en) 1996-11-25
KR970700513A (ko) 1997-02-12
JPH09508272A (ja) 1997-08-26
ES2270425T3 (es) 2007-04-01
EP1759709B1 (de) 2013-02-27
NO2017040I1 (no) 2017-08-01
NO2006008I2 (no) 2009-06-15
KR100367948B1 (ko) 2003-07-12
NO2006008I1 (no) 2006-08-07
JP2006045237A (ja) 2006-02-16
EP0804237A1 (de) 1997-11-05
WO1995019790A1 (en) 1995-07-27
FR06C0024I1 (de) 2006-10-13
JP4115517B2 (ja) 2008-07-09
DE69535133D1 (de) 2006-09-07
JP2009235078A (ja) 2009-10-15
FI962958L (fi) 1996-09-24
EP0804237B8 (de) 2006-11-08
PT804237E (pt) 2006-10-31
NL300238I2 (nl) 2007-05-01
ES2424292T3 (es) 2013-09-30
HUT75129A (en) 1997-04-28
DK0804237T3 (da) 2006-10-16
CA2182013A1 (en) 1995-07-27
HU9602019D0 (en) 1996-09-30
FR06C0024I2 (fr) 2009-01-02
AU703152B2 (en) 1999-03-18
HU220799B1 (hu) 2002-05-28
MX9602971A (es) 1998-01-31
ATE333895T1 (de) 2006-08-15
FI117509B (fi) 2006-11-15
JP2013173738A (ja) 2013-09-05
NL300238I1 (de) 2006-10-02
PL181827B1 (pl) 2001-09-28
EP0804237B1 (de) 2006-07-26
DE69535133T2 (de) 2008-08-21
EP1759709A1 (de) 2007-03-07
LU91271I2 (fr) 2006-10-02
NO963097D0 (no) 1996-07-24
AU1696095A (en) 1995-08-08
NO963097L (no) 1996-09-24
NO2017040I2 (no) 2018-08-28
CN1211123C (zh) 2005-07-20
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
JP5487382B2 (ja) 2014-05-07
NZ279730A (en) 1998-04-27
CA2182013C (en) 2007-07-17
JP2013165718A (ja) 2013-08-29
DK1759709T3 (da) 2013-06-10

Similar Documents

Publication Publication Date Title
NO319867B1 (no) Humaniserte antistoffer mot leukocytt-adhesjonsmolekyl VLA-4, bindingsfragment derav, farmasoytisk preparat omfattende det humaniserte antistoffet eller et bindingsfragment derav, samt anvendelser av det humaniserte antistoff.
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
DK0918797T4 (en) A humanized immunoglobulin reactive with alpha4beta7 integrin
KR100240308B1 (ko) 인간화된단클론성항체및혼성단클론성항체
AU747898B2 (en) Monoclonal antibodies to human CD6
JP3276369B2 (ja) 改良ヒト化免疫グロブリン
EP2070948B1 (de) Humanisierter Anti-CD4-Antikörper mit immunsuppressiven Eigenschaften
PL180157B1 (en) Humanised antibodies and their application
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
CN115947855B (zh) 抗cd24抗体的制备及其用途
HK1132278B (en) Humanized anti-cd4 antibody with immunosuppressive properties
HK1088337B (en) Humanized anti-cd4 antibody with immunosuppressive properties

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: TYSABRI - NATALIZUMAB; NAT. REG. NO/DATE: EU106346001NO 20060713

Spc suppl protection certif: 2006008

Filing date: 20060807

Extension date: 20200125

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: TYSABRI - NATALIZUMAB; NAT. REG. NO/DATE: EU106346001NO 20060713

Spc suppl protection certif: 2006008

Filing date: 20060807

Extension date: 20200125

MK1K Patent expired
SPCE Application to extend a supplementary protection certificate (spc)

Free format text: PRODUCT NAME: NATALIZUMAB, ANTI ALFA-4 INTEGRIN HUMANISERT MONOKLONALT ANTISTOFF; NAT. REG. NO/DATE: EU/1/06/346/001 20060627; FIRST REG. NO/DATE: EU , EU/1/06/346/001 20060627

Spc suppl protection certif: 2017040

Filing date: 20170801

SPCH Extension of a supplementary protection certificate (spc) granted

Free format text: PRODUCT NAME: NATALIZUMAB, ANTI ALFA-4 INTEGRIN HUMANISERT MONOKLONALT ANTISTOFF; NAT. REG. NO/DATE: EU/1/06/346/001 20060627; FIRST REG. NO/DATE: EU , EU/1/06/346/001 20060627

Spc suppl protection certif: 2017040

Filing date: 20170801

SPCX Expiry of an spc

Spc suppl protection certif: 2006008